Share this article on:

Characteristics of B-Cell Lymphomas in HIV/HCV-Coinfected Patients During the Combined Antiretroviral Therapy Era: An ANRS CO16 LYMPHOVIR Cohort Study

Terrier, Benjamin MD, PhD*; Costagliola, Dominique MD, PhD†,‡,§; Prevot, Sophie MD, PhD‖,¶; Chavez, Houria MD, PhD#,**; Missy, Pascale‡,§; Rince, Patricia MD¶,#; Costello, Regis MD, PhD††; Escaut, Lelia MD‡‡; Gabarre, Jean MD§§; Joly, Bertrand MD‖‖; Letranchant, Lorraine MD, PhD¶¶; Le Gouill, Steven MD, PhD##; Morineau-Le Houssine, Pascale MD***; Simon, Anne MD; Canioni, Danielle MD, PhD†††; Hermine, Olivier MD, PhD‡‡‡; Cacoub, Patrice MD, PhD*; Taoufik, Yassine MD, PhD¶,#,**; Raphael, Martine MD, PhD¶,#,§§§; Besson, Caroline MD, PhD¶,#,**

JAIDS Journal of Acquired Immune Deficiency Syndromes: 1 June 2013 - Volume 63 - Issue 2 - p 249–253
doi: 10.1097/QAI.0b013e31828a77f0
Brief Report: Epidemiology and Prevention

Abstract: Hepatitis C virus (HCV) infection is frequent among HIV-infected patients. We describe, the characteristics of 6 HIV/HCV-coinfected patients with B-cell non–Hodgkin lymphoma (NHL) included in a prospective cohort study of HIV-related lymphomas. Five of the 6 cases had features of marginal zone/lymphoplasmacytic NHL versus 1 of 33 HIV only–infected patients. Remarkably, anti-HCV treatment led to a hematological response in a patient with splenic marginal zone lymphoma. This supports the role of chronic antigenic stimulation by HCV on lymphomagenesis and further evaluation of HCV antiviral therapy in coinfected patients with NHL.

*Department of Internal Medicine II, Université Paris 6 Pierre et Marie Curie UMR S 943, Paris, France;

Department of Internal Medicine I, Université Paris 6 Pierre et Marie Curie UMR S 943, Paris, France;

INSERM U943, Université Paris 6 Pierre et Marie Curie UMR S 943, Paris, France;

§Université Paris 6 Pierre et Marie Curie UMR S 943, Paris, France;

Department of Pathology, Hôpital Antoine Béclère, AP-HP, Clamart, Université Paris-Sud, UFR Médecine, Le Kremlin-Bicêtre, Paris, France;

Université Paris-Sud, UFR Médecine, Le Kremlin-Bicêtre, F-94275, Paris, France;

#Hematology and Immunology Department, AP-HP, le Kremlin-Bicêtre, Paris, France;

**Inserm U-1012, Le Kremlin-Bicêtre, Paris, France;

††Department of Hematology, Hôpital La Conception, Marseille, Paris, France;

‡‡Department of Infectious Diseases, AP-HP, le Kremlin-Bicêtre, Paris, France;

§§Department of Hematology, Groupe Hospitalier Pitié-Salpétrière, AP-HP, Université Paris 6 Pierre et Marie Curie UMR S 943, Paris, France;

‖‖Department of Hematology, Centre Hospitalier Sud-Francilien, Corbeil-Essonne, Paris, France;

¶¶Department of Infectious Diseases, CHU, Vandoeuvre Les Nancy;

##Department of Hematology, CHU, Nantes, France;

***Department of Infectious Diseases, CHU, Nantes, France;

†††Department of Pathology, APHP, Hôpital Necker-Enfants Malades, Paris F-75015, France;

‡‡‡Department of Hematology, APHP, Hôpital Necker-Enfants Malades, Paris, France; and

§§§CNRS UMR 8126, IGR, Villejuif, France.

Correspondence to: Dr Caroline Besson, MD, PhD, Department of Hematology, Hôpital Bicêtre, 78 avenue du Général Leclerc, 94275 Le Kremlin-Bicêtre, Paris, France (e-mail: caroline.besson@bct.aphp.fr).

Supported by funding from ANRS (French agency for AIDS and viral hepatitis).

The authors have no conflicts of interest to disclose.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).

Received July 14, 2012

Accepted November 15, 2012

© 2013 by Lippincott Williams & Wilkins